News & Updates
Filter by Specialty:
OASIS-1: Thumbs up for mirikizumab in moderate-to-severe plaque psoriasis
The interleukin (IL)-23 inhibitor mirikizumab demonstrates superior efficacy in the treatment of patients with moderate-to-severe plaque psoriasis as compared with placebo, with initial responses during induction preserved through the maintenance phase, according to the results of the phase III OASIS-1 trial.
OASIS-1: Thumbs up for mirikizumab in moderate-to-severe plaque psoriasis
23 Aug 2022
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
Treatment with secukinumab 300 mg significantly improves symptoms of biologic-naïve patients with psoriatic arthritis (PsA) compared with placebo, results from the CHOICE study have shown.
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
12 Aug 2022
Antenatal vitamin D supplementation may curb risk of infant eczema
Infants born to mothers who popped vitamin D during pregnancy are less likely to develop atopic eczema compared with their counterparts whose mothers received placebo, as shown in the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS).
Antenatal vitamin D supplementation may curb risk of infant eczema
01 Aug 2022
Abrocitinib safe, effective in moderate-to-severe atopic dermatitis after dupilumab use
Treatment with abrocitinib is both safe and effective in patients with moderate-to-severe atopic dermatitis (AD), regardless of prior dupilumab response status, a study has shown.
